Project Grant R43AI192098
Award Date 8/26/26
Completion Date 7/31/28
Dollars Obligated $300K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92618, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of California, San Diego $439,375 on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate S protein as a vaccine candidate against Group A Streptococcus. The funded research aims to advance S protein as a protective vaccine against GAS, addressing a pathogen responsible for an estimated 700 million infections and half a million deaths annually....
- The National Institute of Allergy and Infectious Diseases awarded the University of California, San Diego $720,021 on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on antibody interactions with M and M-like proteins of Streptococcus pyogenes (Group A Streptococcus). The project addresses the challenge of developing broadly protective immunization strategies against Strep A, a major global pathogen, by designing M protein-based...
- Federal Project Grant Award Summary Antigen Discovery Inc. (ADI), doing business as Immport Therapeutics Inc., received a $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 12, 2025, with completion targeted for July 31, 2027. The award supports the development and optimization of novel cryptosporidium vaccine candidates through production of purified...
- Federal Project Grant Award Summary Award Details: Abvacc, Inc. received a $638,953 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award was issued on August 22, 2025, with a completion date of July 31, 2030, and performance will be conducted in Rockville, Maryland. Products and Services: The grant funds development of an immunotherapeutic antibody cocktail for treating...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $148,614 to Massachusetts Institute of Technology on January 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop glycopolymers designed to enhance interactions between immune cells and pathogenic bacteria, creating "cellular glues" that leverage the body's innate immune mechanisms as an alternative to...
- The National Institute of Allergy and Infectious Diseases awarded Iaso Therapeutics Inc. $599,998 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a multi-antigen Staphylococcus aureus vaccine using a proprietary mutant bacteriophage platform. Iaso will conduct two research aims over the period of performance through June 30, 2028. In Aim 1, the company will evaluate the protective efficacy of an MQB-PNAG26 conjugate vaccine in a S. aureus...
- The National Institute of Allergy and Infectious Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $228,462 on May 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a modular platform for antigen engineering termed LYGENs (lysosome-targeting antigens) that enhances CD4 T cell responses against cancer and infectious disease. The project introduces fusion constructs pairing microbial antigens from Listeria monocytogenes...
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute $3.679 million on August 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop self-assembling protein nanoparticles presenting stabilized hemagglutinin, neuraminidase, and M2E antigens for universal influenza vaccine development. The research addresses the structural and immunological challenges of creating a vaccine effective against both seasonal and pandemic...
- The National Institute of Allergy and Infectious Diseases awarded Northeastern University $261,675 on July 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct exploratory research on streptothricin derivatization against gram-negative ESKAPE pathogens. The research explores synthetic modification of the gulosamine sugar moiety of streptothricins—antibiotics discovered over 70 years ago that inhibit bacterial protein translation. Preliminary data...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $267,000 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research decoding gasdermin D (GSDMD) pore clustering as a regulatory checkpoint controlling pyroptosis, a lytic and inflammatory form...